List of bibliographic references
Number of relevant bibliographic references: 10.
| Ident. | Authors (with country if any) | Title |
|---|
| 000159 (2017) |
Miguel Martin [Espagne] ; Frankie A. Holmes [États-Unis] ; Bent Ejlertsen [Danemark] ; Suzette Delaloge [France] ; Beverly Moy [États-Unis] ; Hiroji Iwata [Japon] ; Gunter Von Minckwitz [Allemagne] ; Stephen K L. Chia [Canada] ; Janine Mansi [Royaume-Uni] ; Carlos H. Barrios [Brésil] ; Michael Gnant [Autriche] ; Zorica Tomaševi [Serbie] ; Neelima Denduluri [États-Unis] ; Robert Šeparovi [Croatie] ; Erhan Gokmen [Turquie] ; Anna Bashford [Nouvelle-Zélande] ; Manuel Ruiz Borrego [Espagne] ; Sung-Bae Kim [Corée du Sud] ; Erik Hugger Jakobsen [Danemark] ; Audrone Ciceniene [Lituanie] ; Kenichi Inoue [Japon] ; Friedrich Overkamp [Allemagne] ; Joan B. Heijns [Pays-Bas] ; Anne C. Armstrong [Royaume-Uni] ; John S. Link [États-Unis] ; Anil Abraham Joy [Canada] ; Richard Bryce [États-Unis] ; Alvin Wong [États-Unis] ; Susan Moran [États-Unis] ; Bin Yao [États-Unis] ; Feng Xu [États-Unis] ; Alan Auerbach [États-Unis] ; Marc Buyse [Belgique] ; Arlene Chan [Australie] | Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. |
| 000584 (2016) |
Arlene Chan [Australie] ; Suzette Delaloge [France] ; Frankie A. Holmes [États-Unis] ; Beverly Moy [États-Unis] ; Hiroji Iwata [Japon] ; Vernon J. Harvey [Nouvelle-Zélande] ; Nicholas J. Robert [États-Unis] ; Tajana Silovski [Croatie] ; Erhan Gokmen [Turquie] ; Gunter Von Minckwitz [Allemagne] ; Bent Ejlertsen [Danemark] ; Stephen K L. Chia [Canada] ; Janine Mansi [Royaume-Uni] ; Carlos H. Barrios [Brésil] ; Michael Gnant [Autriche] ; Marc Buyse [Belgique] ; Ira Gore [États-Unis] ; John Smith [États-Unis] ; Graydon Harker [États-Unis] ; Norikazu Masuda [Japon] ; Katarina Petrakova [République tchèque] ; Angel Guerrero Zotano [Espagne] ; Nicholas Iannotti [États-Unis] ; Gladys Rodriguez [États-Unis] ; Pierfrancesco Tassone [Italie] ; Alvin Wong [États-Unis] ; Richard Bryce [États-Unis] ; Yining Ye [États-Unis] ; Bin Yao [États-Unis] ; Miguel Martin [Espagne] | Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. |
| 000634 (2016) |
Kathrin Strasser-Weippl [Autriche] ; Nora Horick [États-Unis] ; Ian E. Smith [Royaume-Uni] ; Joyce O'Shaughnessy [États-Unis] ; Bent Ejlertsen [Danemark] ; Frances Boyle [Australie] ; Aman U. Buzdar [États-Unis] ; Pierre Fumoleau [France] ; William Gradishar [États-Unis] ; Miguel Martin [Espagne] ; Beverly Moy [États-Unis] ; Martine Piccart-Gebhart [Belgique] ; Kathleen I. Pritchard [Canada] ; Deborah Lindquist [États-Unis] ; Erica Rappold [États-Unis] ; Dianne M. Finkelstein [États-Unis] ; Paul E. Goss [États-Unis] | Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy. |
| 000905 (2015) |
Kathrin Strasser-Weippl [Autriche] ; Nora Horick [États-Unis] ; Ian E. Smith ; Joyce O Haughnessy [États-Unis] ; Bent Ejlertsen [Danemark] ; Frances Boyle ; Aman U. Buzdar [États-Unis] ; Pierre Fumoleau [France] ; William Gradishar [États-Unis] ; Miguel Martin [Espagne] ; Beverly Moy [États-Unis] ; Martine Piccart-Gebhart [Belgique] ; Kathleen I. Pritchard [Canada] ; Deborah Lindquist [États-Unis] ; Erica Rappold [États-Unis] ; Dianne M. Finkelstein [États-Unis] ; Paul E. Goss [États-Unis] | Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy |
| 000931 (2015) |
Frances M. Boyle [Australie] ; Ian E. Smith [Royaume-Uni] ; Joyce O'Shaughnessy [États-Unis] ; Bent Ejlertsen [Danemark] ; Aman U. Buzdar [États-Unis] ; Pierre Fumoleau [France] ; William Gradishar [États-Unis] ; Miguel Martin [Espagne] ; Beverly Moy [États-Unis] ; Martine Piccart-Gebhart [Belgique] ; Kathleen I. Pritchard [Canada] ; Deborah Lindquist [États-Unis] ; Mayur Amonkar [Royaume-Uni] ; Yingjie Huang [Royaume-Uni] ; Erica Rappold [Royaume-Uni] ; Lisa S. Williams [Royaume-Uni] ; Jing Wang-Silvanto [Royaume-Uni] ; Tomomi Kaneko [Royaume-Uni] ; Dianne M. Finkelstein [États-Unis] ; Paul E. Goss [États-Unis] | Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer. |
| 000D89 (2013) |
Heather-Jane Au [Canada] ; Wolfgang Eiermann [Allemagne] ; Nicholas J. Robert [États-Unis] ; Tadeusz Pie Kowski [Pologne] ; John Crown [Irlande (pays)] ; Miguel Martin [Espagne] ; Marek Pawlicki [Pologne] ; Arlene Chan [Australie] ; John Mackey [Canada] ; John Glaspy [États-Unis] ; Tamás Pintér [Hongrie] ; Mei-Ching Liu [Taïwan] ; Tommy Fornander [Suède] ; Sandeep Sehdev [Canada] ; Jean-Marc Ferrero [France] ; Valerie Bée [France] ; Maria J. Santana [Canada] ; Dave P. Miller [États-Unis] ; Deepa Lalla [États-Unis] ; Dennis J. Slamon [États-Unis] | Health-Related Quality of Life With Adjuvant Docetaxel- and Trastuzumab-Based Regimens in Patients with Node-Positive and High-Risk Node-Negative, HER2-Positive Early Breast Cancer: Results from the BCIRG 006 Study |
| 001169 (2012) |
Miguel Martin [Espagne] ; Richard Bell [Australie] ; Hugues Bourgeois [France] ; Adam Brufsky [États-Unis] ; Ingo Diel [Allemagne] ; Alexandru Eniu [Roumanie] ; Lesley Fallowfield [Royaume-Uni] ; Yasuhiro Fujiwara [Japon] ; Jacek Jassem [Pologne] ; Alexander H. G. Paterson [Canada] ; Diana Ritchie [Royaume-Uni] ; Gunther G. Steger [Autriche] ; Alison Stopeck [États-Unis] ; Charles Vogel [États-Unis] ; Michelle Fan [États-Unis] ; QI JIANG [Allemagne] ; Karen Chung [États-Unis] ; Roger Dansey [États-Unis] ; Ada Braun [États-Unis] | Bone-Related Complications and Quality of Life in Advanced Breast Cancer: Results from a Randomized Phase III Trial of Denosumab versus Zoledronic Acid |
| 001341 (2011) |
Wolfgang Eiermann [Allemagne, Pologne, Irlande (pays), Espagne, Australie, États-Unis, Canada, Suisse, France, Belgique] ; Tadeusz Pienkowski ; John Crown ; Saeed Sadeghi ; Miguel Martin ; Arlene Chan ; Mansoor Saleh ; Sandeep Sehdev ; Louise Provencher ; Vladimir Semiglazov ; Michael Press ; Guido Sauter ; Mary-Ann Lindsay ; Alessandro Riva ; Marc Buyse ; Philippe Drevot ; Henry Taupin ; John R. Mackey | Phase III Study of Doxorubicin/Cyclophosphamide With Concomitant Versus Sequential Docetaxel As Adjuvant Treatment in Patients With Human Epidermal Growth Factor Receptor 2-Normal, Node-Positive Breast Cancer: BCIRG-005 Trial |
| 001411 (2011) |
Dennis Slamon [États-Unis] ; Wolfgang Eiermann [Allemagne] ; Nicholas Robert [États-Unis] ; Tadeusz Pienkowski [Pologne] ; Miguel Martin [Espagne] ; Michael Press [États-Unis] ; John Mackey [Canada] ; John Glaspy [États-Unis] ; Arlene Chan [Australie] ; Marek Pawlicki [États-Unis] ; Tamas Pinter [Hongrie] ; Vicente Valero [États-Unis] ; Mei-Ching Liu [Taïwan] ; Guido Sauter [Allemagne] ; Gunter Von Minckwitz [Allemagne] ; Frances Visco [États-Unis] ; Valerie Bee [France] ; Marc Buyse [Belgique] ; Belguendouz Bendahmane [France] ; Isabelle Tabah-Fisch [France] ; Mary-Ann Lindsay [France] ; Alessandro Riva [France] ; John Crown [Israël] | Adjuvant Trastuzumab in HER2-Positive Breast Cancer |
| 001A76 (2005) |
Shailendra Verma [Canada] ; Dominique Maraninchi [France] ; Joyce O'Shaughnessy [États-Unis] ; Carol Jamieson [États-Unis] ; Stephen Jones [États-Unis] ; Miguel Martin [Espagne] ; Joseph Mckendrick [Australie] ; David Miles [Royaume-Uni] ; Chris Twelves [Royaume-Uni] ; John Hornberger [États-Unis] | Capecitabine plus docetaxel combination therapy : Cost-effectiveness in patients with anthracycline-pretreated advanced breast carcinoma |
List of associated KwdEn.i
Nombre de
documents | Descripteur |
|---|
| 4 | Antineoplastic agent |
| 4 | Breast Neoplasms (drug therapy) |
| 4 | Breast Neoplasms (pathology) |
| 4 | Chemotherapy, Adjuvant |
| 4 | Female |
| 4 | Humans |
| 4 | Middle Aged |
| 3 | Adult |
| 3 | Aged |
| 3 | Breast Neoplasms (mortality) |
| 3 | Breast cancer |
| 3 | Disease-Free Survival |
| 3 | Human |
| 3 | Proportional Hazards Models |
| 3 | Receptor, ErbB-2 (metabolism) |
| 3 | Treatment Outcome |
| 2 | Advanced stage |
| 2 | Aged, 80 and over |
| 2 | Antineoplastic Agents (therapeutic use) |
| 2 | Breast Neoplasms (enzymology) |
| 2 | Cancerology |
| 2 | Clinical trial |
| 2 | Comparative study |
| 2 | Docetaxel |
| 2 | Follow-Up Studies |
| 2 | Human Epidermal growth factor Receptor 2 |
| 2 | Kaplan-Meier Estimate |
| 2 | Neoplasm Recurrence, Local |
| 2 | Neoplasm Staging |
| 2 | Phase III trial |
| 2 | Quinazolines (therapeutic use) |
| 2 | Receptor, ErbB-2 (antagonists & inhibitors) |
| 2 | Receptor, ErbB-2 (genetics) |
| 1 | Adjuvant |
| 1 | Adjuvant treatment |
| 1 | Anthracyclins |
| 1 | Antineoplastic Agents (adverse effects) |
| 1 | Antineoplastic Combined Chemotherapy Protocols (administration & dosage) |
| 1 | Antineoplastic Combined Chemotherapy Protocols (therapeutic use) |
| 1 | Antiresorptive agent |
| 1 | Bone |
| 1 | Breast Neoplasms (genetics) |
| 1 | Breast Neoplasms (metabolism) |
| 1 | Breast Neoplasms (surgery) |
| 1 | Breast carcinoma |
| 1 | C-Onc gene |
| 1 | Capecitabine |
| 1 | Chemotherapy |
| 1 | Combined treatment |
| 1 | Complication |
| 1 | Cost efficiency analysis |
| 1 | Costs |
| 1 | Cyclophosphamide |
| 1 | Denosumab |
| 1 | Dose-Response Relationship, Drug |
| 1 | Double-Blind Method |
| 1 | Doxorubicin |
| 1 | Drug Administration Schedule |
| 1 | Economic aspect |
| 1 | Health economy |
| 1 | Immunomodulator |
| 1 | In Situ Hybridization, Fluorescence |
| 1 | Internationality |
| 1 | Malignant tumor |
| 1 | Mammary gland |
| 1 | Mastectomy (methods) |
| 1 | Medicine |
| 1 | Metastasis |
| 1 | Molecular Targeted Therapy |
| 1 | Monoclonal antibody |
| 1 | Neoplasm Invasiveness (pathology) |
| 1 | Patient |
| 1 | Patient Selection |
| 1 | Precision Medicine |
| 1 | Prognosis |
| 1 | Protein Kinase Inhibitors (adverse effects) |
| 1 | Protein Kinase Inhibitors (therapeutic use) |
| 1 | Protooncogene |
| 1 | Quality of Life |
| 1 | Quality of life |
| 1 | Quinazolines (adverse effects) |
| 1 | Quinolines (administration & dosage) |
| 1 | Quinolines (adverse effects) |
| 1 | Randomization |
| 1 | Receptor, ErbB-2 (biosynthesis) |
| 1 | Receptors, Estrogen (metabolism) |
| 1 | Receptors, Progesterone (metabolism) |
| 1 | Sequential |
| 1 | Signal Transduction (drug effects) |
| 1 | Surveys and Questionnaires |
| 1 | Survival Analysis |
| 1 | Time Factors |
| 1 | Trastuzumab |
| 1 | Trastuzumab (administration & dosage) |
| 1 | Trastuzumab (adverse effects) |
| 1 | Young Adult |
| 1 | Zoledronic acid |
| 1 | erbB2 Gene |
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Canada/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/Canada/Analysis/Author.i -k "Miguel Martin"
HfdIndexSelect -h $EXPLOR_AREA/Data/Canada/Analysis/Author.i \
-Sk "Miguel Martin" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Canada/Analysis/biblio.hfd
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Canada
|étape= Analysis
|type= indexItem
|index= Author.i
|clé= Miguel Martin
}}
| This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024 |  |
